PDCD1 and cancer: When the objective response rate (ORR) seen with immune checkpoint inhibitor monotherapy (anti-PD-1 or anti-PD-L1 antibody) was plotted against the median TMB for 27 cancer types, a significant correlation between ORR and TMB was observed (Fig. 5) [32].